{"id":"desirudin","rwe":[],"tags":[{"label":"Anti-coagulant","category":"class"},{"label":"Peptide","category":"modality"},{"label":"Prothrombin","category":"target"},{"label":"F2","category":"gene"},{"label":"B01AE01","category":"atc"},{"label":"Active","category":"status"},{"label":"Prevention of deep vein thrombosis","category":"indication"},{"label":"Marathon Pharms Llc","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Anticoagulants","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Fibrinolytic Agents","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"contraindications":["Bacterial endocarditis","Blood coagulation disorder","Diabetic retinopathy","Gastrointestinal hemorrhage","Hemophilia","Hemorrhagic cerebral infarction","Hypertensive urgency","Impaired renal function disorder","Intracranial hemorrhage","Local anesthetic intrathecal block","Lumbar puncture","Ocular Bleeding","Operation on brain","Placement of Epidural Catheter","Procedure on central nervous system","Procedure on spine","Pulmonary hemorrhage","Retinal hemorrhage","Significant Bleeding","Surgical procedure"]},"trials":[],"aliases":[],"company":"Marathon Pharms Llc","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DESIRUDIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:12:36.219913+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:12:41.615393+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESIRUDIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:12:42.676135+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Thrombin inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:43.717532+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201662/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:43.380549+00:00"}},"allNames":"revasc","offLabel":[],"synonyms":["desirudin recombinant","desulfatohirudin","desulphatohirudin","IK-HIR02","desirudin","revasc"],"timeline":[{"date":"2003-04-04","type":"positive","source":"DrugCentral","milestone":"FDA approval (Marathon Pharms Llc)"}],"aiSummary":"Revasc (Desirudin) is a small molecule anti-coagulant that targets prothrombin. It was originally developed by Marathon Pharms LLC and remains under their ownership. FDA approved in 2003 for the prevention of deep vein thrombosis, Revasc works by inhibiting the conversion of prothrombin to thrombin, thereby preventing blood clot formation. As a patented medication, its commercial status is subject to intellectual property protection. Key safety considerations include the risk of bleeding.","approvals":[{"date":"2003-04-04","orphan":false,"company":"MARATHON PHARMS LLC","regulator":"FDA"}],"brandName":"Revasc","ecosystem":[{"indication":"Prevention of deep vein thrombosis","otherDrugs":[{"name":"dabigatran etexilate","slug":"dabigatran-etexilate","company":"Boehringer Ingelheim"},{"name":"edoxaban","slug":"edoxaban","company":"Daiichi Sankyo"},{"name":"fondaparinux","slug":"fondaparinux","company":"Mylan Ireland Ltd"},{"name":"heparin","slug":"heparin","company":"Organon Usa Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Prothrombin","novelty":"Follow-on","targets":[{"gene":"F2","source":"DrugCentral","target":"Prothrombin","protein":"Prothrombin"}],"moaClass":"Thrombin Inhibitors","modality":"Small Molecule","drugClass":"Anti-coagulant","explanation":"","oneSentence":"","technicalDetail":"Revasc (Desirudin) is a direct thrombin inhibitor that selectively binds to and inhibits the activity of thrombin, a key enzyme in the coagulation cascade, thereby preventing the conversion of fibrinogen to fibrin and subsequent clot formation."},"commercial":{"launchDate":"2003","_launchSource":"DrugCentral (FDA 2003-04-04, MARATHON PHARMS LLC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2990","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DESIRUDIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESIRUDIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:34:16.827386","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:12:44.994002+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"lepirudin","drugSlug":"lepirudin","fdaApproval":"1998-03-06","relationship":"same-class"},{"drugName":"argatroban","drugSlug":"argatroban","fdaApproval":"2000-06-30","patentExpiry":"Sep 26, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"bivalirudin","drugSlug":"bivalirudin","fdaApproval":"2000-12-15","patentExpiry":"May 20, 2039","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dabigatran etexilate","drugSlug":"dabigatran-etexilate","fdaApproval":"2010-10-19","patentExpiry":"Mar 7, 2026","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"desirudin","indications":{"approved":[{"name":"Prevention of deep vein thrombosis","source":"DrugCentral","snomedId":439993001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"lepirudin","brandName":"lepirudin","genericName":"lepirudin","approvalYear":"1998","relationship":"same-class"},{"drugId":"argatroban","brandName":"argatroban","genericName":"argatroban","approvalYear":"2000","relationship":"same-class"},{"drugId":"bivalirudin","brandName":"bivalirudin","genericName":"bivalirudin","approvalYear":"2000","relationship":"same-class"},{"drugId":"dabigatran-etexilate","brandName":"dabigatran etexilate","genericName":"dabigatran etexilate","approvalYear":"2010","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07426107","phase":"","title":"Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revascularization","status":"NOT_YET_RECRUITING","sponsor":"Xiao Hui Zhang","startDate":"2026-02-25","conditions":["Immune Thrombocytopenic Purpura","Coronary Artery Disease"],"enrollment":600,"completionDate":"2029-02-25"},{"nctId":"NCT07223437","phase":"NA","title":"REVASC-PAD: REstricted VASCular Exercise for Peripheral Arterial Disease - A Feasibility Study at University of Tennessee Medical Center","status":"NOT_YET_RECRUITING","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2025-11-05","conditions":["Peripheral Arterial Disease"],"enrollment":81,"completionDate":"2027-11-05"},{"nctId":"NCT02797158","phase":"NA","title":"Post TAVI Coronary REVASCularisation Guided by Myocardial Perfusion Imaging: a Prospective Open Label Pilot Study: The REVASC-TAVI Study","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2016-06-23","conditions":["Severe and Symptomatic Aortic Stenosis","Stable Coronary Disease"],"enrollment":71,"completionDate":"2019-07-15"},{"nctId":"NCT01976065","phase":"PHASE1","title":"Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots","status":"COMPLETED","sponsor":"Kenneth Hargreaves","startDate":"2014-09","conditions":["Pulp Necrosis","Regeneration"],"enrollment":125,"completionDate":"2018-09-24"},{"nctId":"NCT03289728","phase":"NA","title":"Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2018-04-04","conditions":["Myocardial Infarction"],"enrollment":1756,"completionDate":"2024-06"},{"nctId":"NCT02060630","phase":"NA","title":"Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia","status":"COMPLETED","sponsor":"Carelon Research","startDate":"2014-08","conditions":["Critical Limb Ischemia"],"enrollment":1843,"completionDate":"2022-03-01"},{"nctId":"NCT02075502","phase":"NA","title":"Community Walking Exercise for Patients With Peripheral Artery Disease","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2014-02-01","conditions":["Peripheral Artery Disease"],"enrollment":70,"completionDate":"2020-02-12"},{"nctId":"NCT00329433","phase":"PHASE2,PHASE3","title":"Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2006-05","conditions":["Deep Venous Thrombosis"],"enrollment":120,"completionDate":"2008-10"},{"nctId":"NCT00424450","phase":"","title":"Assessment of Bypass Surgery and Balloon Angioplasty Effects in Peripheral Arterial Disease Using Contrast Ultrasound","status":"COMPLETED","sponsor":"University Hospital Freiburg","startDate":"2006-10","conditions":["Peripheral Arterial Disease"],"enrollment":30,"completionDate":"2009-07"},{"nctId":"NCT00787332","phase":"PHASE4","title":"A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome","status":"TERMINATED","sponsor":"Canyon Pharmaceuticals, Inc.","startDate":"2008-09","conditions":["Suspected Heparin-Induced Thrombocytopenia"],"enrollment":16,"completionDate":"2009-12"},{"nctId":"NCT00913133","phase":"PHASE4","title":"Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis","status":"COMPLETED","sponsor":"Canyon Pharmaceuticals, Inc.","startDate":"2010-03","conditions":["Thrombosis"],"enrollment":516,"completionDate":"2011-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000188382","MMSL":"17230","NDDF":"007722","UNII":"U0JZ726775","VUID":"4032625","CHEBI":"CHEBI:140427","VANDF":"4032625","INN_ID":"7193","RXNORM":"114934","UMLSCUI":"C0378366","chemblId":"CHEMBL1201662","ChEMBL_ID":"CHEMBL1201662","KEGG_DRUG":"D03692","DRUGBANK_ID":"DB11095","PUBCHEM_CID":"16129703","SNOMEDCT_US":"319718008","IUPHAR_LIGAND_ID":"6458","MESH_SUPPLEMENTAL_RECORD_UI":"C060225"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2003-","companyName":"Marathon Pharms Llc","relationship":"Original Developer"}],"publicationCount":75,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"B01AE01","allCodes":["B01AE01"]},"biosimilarFilings":[],"originalDeveloper":"Marathon Pharms Llc","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Marathon Pharms Llc","companyId":"marathon-pharms-llc","modality":"Recombinant protein","firstApprovalDate":"2003","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2003-04-04T00:00:00.000Z","mah":"MARATHON PHARMS LLC","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":null,"brand_name_local":"Revasc","application_number":"EMEA/H/C/000104"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Revasc","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:12:44.994002+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}